Transatlantic Health Policy Transfers: Diagnosing Why European Models Struggle to Take Root in the United States

Introduction: A Tale of Two Systems

When researchers and policymakers examine comparative health data across high-income nations, a persistent anomaly emerges. The United States spends more per capita on healthcare than any other country in the Organisation for Economic Co-operation and Development (OECD), yet ranks near the bottom of that cohort on key outcome measures including life expectancy, preventable mortality, and chronic disease management. Meanwhile, nations such as Germany, the Netherlands, Denmark, and France consistently achieve superior population health metrics at substantially lower cost. The logical inference—that the United States should adopt proven European policy instruments—has driven decades of reform advocacy. Yet the results of such efforts have been, at best, partial.

This article does not argue that European health systems are without flaws, nor that American healthcare is without merit. Rather, it examines the specific mechanisms by which evidence-based policies that function effectively within European institutional environments encounter systemic resistance when introduced into the American context. Three primary domains of friction are identified: regulatory architecture, economic incentive structures, and cultural-political norms surrounding healthcare as a social good.

Regulatory Architecture: A Fragmented Foundation

Perhaps the most fundamental barrier to policy transfer is the structural difference between European and American regulatory environments. Most high-performing European health systems operate within unified or tightly coordinated national frameworks. Germany's statutory health insurance (Gesetzliche Krankenversicherung) system, for example, functions through a federally regulated network of non-profit sickness funds operating under standardized benefit packages. Reimbursement schedules, coverage mandates, and quality benchmarks are negotiated at the national level, creating a coherent policy environment.

The United States, by contrast, operates through a patchwork of overlapping jurisdictions. Federal programs—Medicare, Medicaid, and the Children's Health Insurance Program (CHIP)—coexist with fifty distinct state regulatory regimes and a large private insurance market governed by the Employee Retirement Income Security Act (ERISA), which substantially limits states' ability to mandate coverage standards. This fragmentation means that a policy instrument designed to function as a system-wide intervention must instead navigate dozens of regulatory environments simultaneously.

Preventive care reimbursement offers an instructive case study. Nordic countries have long demonstrated that robust public reimbursement for preventive services—including lifestyle counseling, mental health screening, and early chronic disease intervention—produces measurable long-term reductions in acute care utilization and cost. The Affordable Care Act (ACA) attempted a partial adaptation of this principle through its preventive services mandate. However, ongoing legal challenges, inconsistent state-level implementation, and the exclusion of large segments of the uninsured population have limited its population-level impact. A policy instrument designed for a unified system cannot easily be retrofitted onto a fragmented one.

Economic Incentive Structures: When Fee-for-Service Meets Value-Based Logic

Beyond regulatory architecture, the economic logic embedded within American healthcare creates powerful countervailing forces against European-style policy transfers. The dominant fee-for-service reimbursement model in the United States financially rewards procedural volume rather than patient outcomes. Hospitals, specialist physicians, and diagnostic facilities derive revenue from the delivery of discrete services; preventive interventions that reduce the need for those services are, in a strict economic sense, contrary to the financial interests of many institutional actors.

European integrated care models—particularly those developed in the Netherlands and the United Kingdom's National Health Service (NHS)—are premised on capitated or bundled payment structures that align provider incentives with long-term patient health. When a Dutch general practitioner coordinates preventive mental health services for a patient, that coordination is financially supported within a system designed to reduce downstream hospitalizations. Transplanting the clinical protocol without transplanting the payment architecture produces predictably weak results.

Medicare's value-based purchasing programs and the Center for Medicare and Medicaid Innovation (CMMI) represent genuine efforts to introduce outcome-oriented payment models. However, research published in peer-reviewed health economics journals consistently finds that these programs have achieved modest and uneven results, partly because they operate as islands of value-based logic within a larger fee-for-service ocean. The incentive environment surrounding them remains fundamentally misaligned.

Cultural and Political Dimensions: Healthcare as Individual Versus Collective Good

Any rigorous analysis of policy transfer must account for the cultural and political norms that shape how populations and their elected representatives conceptualize healthcare. In most Northern and Western European nations, healthcare is broadly understood as a collective social good—a public infrastructure analogous to roads or public education. This shared normative foundation makes universal coverage mandates, redistributive financing mechanisms, and government-negotiated pharmaceutical pricing politically viable.

American political culture, shaped by a distinct tradition of liberal individualism and skepticism toward federal authority, does not share this foundational consensus. Healthcare remains a deeply contested site of ideological conflict, with significant portions of the electorate viewing government involvement in health financing as an infringement on individual liberty and market freedom. This is not merely a rhetorical observation; it has concrete policy consequences. Provisions that would be considered uncontroversial administrative mechanisms in a European context—such as mandatory enrollment in a public insurance scheme or government reference pricing for pharmaceuticals—become politically toxic in the American environment.

The repeated failure to enact meaningful pharmaceutical price negotiation at the federal level, despite broad evidence of its cost-effectiveness from European comparators, illustrates this dynamic clearly. The Inflation Reduction Act of 2022 introduced limited Medicare drug price negotiation for the first time, representing a significant departure from prior policy. However, the scope of that negotiation remains far narrower than the frameworks operating in France, Germany, or the United Kingdom.

Policy Recommendations: Toward Contextually Adapted Transfer

The conclusion that European health policy models are simply inapplicable to the United States would be an overreach. A more productive framing recognizes that successful policy transfer requires contextual adaptation rather than wholesale importation. Several evidence-based recommendations emerge from this analysis.

First, reform advocates should prioritize payment architecture reform as a precondition for clinical model adoption. Introducing integrated mental health or preventive care protocols without first aligning financial incentives is unlikely to achieve population-level impact.

Second, state-level laboratories of policy innovation—already a feature of the American federal system—should be more deliberately leveraged. States such as Vermont, Oregon, and Maryland have experimented with all-payer rate setting and integrated delivery models that approximate European frameworks within the American regulatory context. Rigorous evaluation and dissemination of these experiments is essential.

Third, cross-sector coalitions that include employers, insurers, and patient advocacy organizations are more likely to achieve durable policy change than purely government-led initiatives, given the political economy of American healthcare.

Conclusion

The persistence of the transatlantic health outcome gap is not a mystery, but it is a complex problem. European health policy models carry genuine evidentiary weight, and their successes deserve serious scholarly attention. However, the institutional, economic, and cultural environment of the United States is not a neutral substrate onto which these models can be directly applied. Effective reform requires the difficult work of contextual translation—preserving the evidence-based logic of successful European interventions while redesigning their mechanisms for an environment shaped by fragmented governance, misaligned incentives, and contested normative foundations. That work is possible. It simply demands more rigor than analogy.